ARS Pharmaceuticals (SPRY) Share-based Compensation (2020 - 2026)

ARS Pharmaceuticals has disclosed Share-based Compensation across 7 years of filings, most recently posting $7.4 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $7.4 million, up 40.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.2 million (up 46.64% YoY), and the FY2025 annual result was $22.1 million, up 52.02% from the prior year.
• Share-based Compensation came in at $7.4 million for Q1 2026 at ARS Pharmaceuticals, up from $5.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $7.4 million in Q1 2026 to a low of $264000.0 in Q1 2022.
• The 5-year median for Share-based Compensation is $3.4 million (2024), against an average of $3.5 million.
• Across the five-year window, Share-based Compensation slumped 93.84% in 2022 and soared 752.27% in 2023, its largest moves.
• ARS Pharmaceuticals' Share-based Compensation stood at $4.8 million in 2022, then slumped by 52.17% to $2.3 million in 2023, then soared by 87.14% to $4.3 million in 2024, then surged by 34.58% to $5.7 million in 2025, then grew by 29.39% to $7.4 million in 2026.
• The last three Share-based Compensation figures came in at $7.4 million (Q1 2026), $5.7 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.